Active, not recruitingPhase 1NCT05206357
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Genmab
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- Epcoritamab(drug)
- Enrollment
- 17 enrolled
- Eligibility
- 1-25 years · All sexes
- Timeline
- 2022 – 2028
Study locations (30)
- Lucile Packard Children's Hospital /ID# 240854, Palo Alto, California, United States
- Nicklaus Children's Hospital /ID# 241174, Miami, Florida, United States
- New York Medical College /ID# 239208, Valhalla, New York, United States
- Levine Children's Hospital /ID# 242765, Charlotte, North Carolina, United States
- Cincinnati Childrens Hospital Medical Center /ID# 239823, Cincinnati, Ohio, United States
- Children's Hospital of Philadelphia - Main /ID# 239294, Philadelphia, Pennsylvania, United States
- St Jude Children's Research Hospital /ID# 239184, Memphis, Tennessee, United States
- University of Texas Southwestern Medical Center /ID# 240892, Dallas, Texas, United States
- Children's Hospital at Westmead /ID# 240091, Westmead, New South Wales, Australia
- Royal Children's Hospital /ID# 240384, Parkville, Victoria, Australia
- Perth Children'S Hospital /ID# 240382, Perth, Western Australia, Australia
- Universitair Ziekenhuis Leuven /ID# 242384, Leuven, Vlaams-Brabant, Belgium
- Hospital for Sick Children /ID# 240767, Toronto, Ontario, Canada
- CHU Sainte-Justine /ID# 240766, Montreal, Quebec, Canada
- Fakultní Nemocnice Brno - Jihlavská /ID# 239956, Brno, Brno-mesto, Czechia
- +15 more locations on ClinicalTrials.gov
Collaborators
AbbVie
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05206357 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic